Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 353899

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 353899

Melanoma Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2022 - 2027)

PUBLISHED:
PAGES: 114 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4750
PDF & Excel (Team License: Up to 7 Users)
USD 5250
PDF & Excel (Site License)
USD 6500
PDF & Excel (Corporate License)
USD 8750

Add to Cart

The melanoma diagnostics and therapeutics market is estimated to show good growth due to the increasing incidences of melanoma cases, rising governments initiatives for early detection and skin cancer treatment and rising technological advancements.

There has been a rapid increase in the melanoma cases that is found to be one of the major causes of morbidity and mortality in the US. Melanoma is one of the most common types of cancer in men and women. Among young adults, it is the second most common invasive cancer. According to WHO statistics, there are more than two million people that develops non-melanoma skin cancer, and around 132,000 people that develop melanoma. Therefore the rising number of cases of melanoma will eventually lead to the high CAGR for the melanoma diagnostics and therapeutics market.

Key Market Trends

Immune Therapy is Anticipated to be the Dominant in Therapeutics Segment during the Forecast Period

Immunotherapy is the use of medicines to stimulate a person immune system to recognize and destroy cancer cells effectively. There are several types of immunotherapies available that can be used to treat melanoma cancer.

Immunotherapy is found to hold the largest share that can be attributed to the effectiveness of drugs used in immunotherapy and an increase in their approvals. There are currently many FDA-approved immunotherapy options for melanoma that helps in the growth of the market. There have also many advances in using immunotherapy drugs known as checkpoint inhibitors to treat melanoma. Thus the strong emerging pipeline for melanoma treatment is expected to drive the immunotherapy segment over the forecast period.

North America Dominates the Melanoma Diagnostics and Therapeutics Market

North America holds a dominant share of the market owing to the rising incidence of melanoma and other skin cancers cases in the region. According to the Skin Cancer Foundation, one in every five Americans is likely to develop a kind of skin cancer during his/her lifetime. Furthermore, the American cancer society estimates 91,270 new cases of melanoma in the United States in 2018 alone. These statistics highlight the need for drugs that help in the management of melanoma over the coming years.

The United States government has also developed favorable reimbursement policies for treatment of melanoma diseases that is an attempt to fulfil unmet patient needs. This is expected to provide a healthy platform for growth to the North American market. Furthermore, the presence of numerous new players is expected to drive the overall market.

Competitive Landscape

The market is highly competitive in nature, with many key players involved in market expansion, partnerships, new product development, and R&D to increase market penetration. There are also several products are under clinical trials which are expected to receive approval and thus the market is likely to continue witnessing high competitive rivalry over the forecast period.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 55526

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Melanoma Cases
    • 4.2.2 Rising Governments Initiatives for Early Detection and Skin Cancer Treatment
    • 4.2.3 Rising Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated with the Therapy
    • 4.3.2 Stringent Regulatory Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 By Diagnostics
      • 5.1.1.1 Dermatoscopy Devices
      • 5.1.1.2 Biopsy Devices
    • 5.1.2 By Therapeutics
      • 5.1.2.1 Chemotherapy
      • 5.1.2.2 Biological Therapy
      • 5.1.2.3 Targeted Therapy
      • 5.1.2.4 Immune Therapy
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Diagnostics
    • 6.1.2 Amgen, Inc.
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bayer AG
    • 6.1.5 Bristol-Myers Squibb
    • 6.1.6 Daiichi Sankyo Company Limited
    • 6.1.7 F. Hoffman-La Roche Ltd.
    • 6.1.8 GlaxoSmithKline PLC
    • 6.1.9 Merck & Co., Inc
    • 6.1.10 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!